Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including ...

Patients with appendiceal adenocarcinoma face increased risk of secondary cancers, including colorectal, within 10 years, per ...

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage ...

Impact of baseline alterations in HER2-pathway oncogenic drivers on response to anti-HER2 therapy in patients (pts) with HER2-amplified advanced colorectal cancer (aCRC). This is an ASCO Meeting ...

A phase Ib study of immunotherapy with ex-vivo pre-activated and expanded CBNK cells in combination with cetuximab, in patients with colorectal cancer (CRC) with minimal residual disease (MRD): Final ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Today, on World Cancer Day, we come together to raise awareness, promote early detection and encourage prevention.

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced ...

By studying biomarkers known to be involved in gastrointestinal cancers, researchers have developed a biomarker algorithm that, when combined with a noninvasive method to collect esophageal cells for ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...